PHE - Corporate - A Clinical and Cost Effectiveness Model on Formalising New-born Screening for β-thalassaemia Major
Estimated value
—
Awarded value
£81k
Awarded 30 Oct 2020
Suppliers
1
Lots
1
1 awarded
Published
03 Nov 2020
Deadline 14 Oct 2020
Awarded suppliers· 1 supplier
Awarded 30 Oct 2020 · Contract period 02 Nov 2020 — 28 Apr 2022
Award value
£81k